Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) EBT (2016 - 2025)

Historic EBT for Perspective Therapeutics (CATX) over the last 16 years, with Q3 2025 value amounting to -$26.0 million.

  • Perspective Therapeutics' EBT fell 7172.99% to -$26.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$109.4 million, marking a year-over-year decrease of 9888.34%. This contributed to the annual value of -$81.4 million for FY2024, which is 6553.63% down from last year.
  • Perspective Therapeutics' EBT amounted to -$26.0 million in Q3 2025, which was down 7172.99% from -$22.0 million recorded in Q2 2025.
  • Perspective Therapeutics' EBT's 5-year high stood at $1.3 million during Q2 2021, with a 5-year trough of -$43.2 million in Q4 2024.
  • Its 5-year average for EBT is -$11.3 million, with a median of -$10.9 million in 2023.
  • As far as peak fluctuations go, Perspective Therapeutics' EBT soared by 21329.97% in 2021, and later crashed by 70705.27% in 2023.
  • Perspective Therapeutics' EBT (Quarter) stood at -$1.6 million in 2021, then crashed by 357.29% to -$7.3 million in 2022, then plummeted by 129.39% to -$16.8 million in 2023, then crashed by 156.83% to -$43.2 million in 2024, then soared by 39.91% to -$26.0 million in 2025.
  • Its EBT stands at -$26.0 million for Q3 2025, versus -$22.0 million for Q2 2025 and -$18.2 million for Q1 2025.